X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Ocular Surface

期刊標題檢索 OCUL SURF 最新評論: Can articles related to cataracts be submitted? (2022-09-13)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Ocular Surface]您好,您是該頁面的第 28638 位訪客。

期刊簡介
期刊名稱Ocular Surface Ocular Surface
LetPub Score
8.9
50 ratings
Rate

Reputation
9.8

Influence
8.2

Speed
8.4

期刊簡稱OCUL SURF
ISSN1542-0124
E-ISSN1937-5913
h-index53
CiteScore
CiteScoreSJRSNIPCiteScore Rank
11.601.7251.801
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Ophthalmology
Q14 / 137

自引率 (2023-2024)10.20%自引率趨勢
掲載範囲
The Ocular Surface, a quarterly, a peer-reviewed journal, is an authoritative resource that integrates and interprets major findings in diverse fields related to the ocular surface, including ophthalmology, optometry, genetics, molecular biology, pharmacology, immunology, infectious disease, and epidemiology. Its critical review articles cover the most current knowledge on medical and surgical management of ocular surface pathology, new understandings of ocular surface physiology, the meaning of recent discoveries on how the ocular surface responds to injury and disease, and updates on drug and device development. The journal also publishes select original research reports and articles describing cutting-edge techniques and technology in the field.
Benefits to authors
We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.
Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
官方網站http://www.journals.elsevier.com/the-ocular-surface/
在線稿件提交https://www.editorialmanager.com/THEOCULARSURFACE
開放訪問No
出版商Elsevier Inc.
主題領域医学
出版國/地區UNITED STATES
發行頻率四半期刊行
創刊年2003
每年文章數98每年文章數趨勢
黃金OA百分比30.90%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
OPHTHALMOLOGYSCIEQ14/95
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1542-0124%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: >12 Week(s), or Invited contributions
競爭力 *來自作者的數據: Moderate
參考鏈接
相關期刊 【Ocular Surface】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    PROGRESS IN RETINAL AND EYE RESEARCHH-index: 131

    CiteScore: 34.10
    OPHTHALMOLOGYH-index: 217

    CiteScore: 22.30
    SURVEY OF OPHTHALMOLOGYH-index: 120

    CiteScore: 10.30
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCEH-index: 196

    CiteScore: 6.90
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGYH-index: 67

    CiteScore: 7.60
    AMERICAN JOURNAL OF OPHTHALMOLOGYH-index: 171

    CiteScore: 9.20
    BRITISH JOURNAL OF OPHTHALMOLOGYH-index: 137

    CiteScore: 10.30
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIEH-index: 44

    CiteScore: 3.20
    ACTA OPHTHALMOLOGICAH-index: 77

    CiteScore: 7.60
    CURRENT OPINION IN OPHTHALMOLOGYH-index: 79

    CiteScore: 6.80
    學科內最受檢索的期刊 頁面查看次數
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE67688
    OPHTHALMOLOGY43596
    EXPERIMENTAL EYE RESEARCH43411
    BRITISH JOURNAL OF OPHTHALMOLOGY41008
    EYE40962
    CURRENT EYE RESEARCH38542
    CORNEA37640
    ACTA OPHTHALMOLOGICA37071
    AMERICAN JOURNAL OF OPHTHALMOLOGY35742
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY33294
  •  

    Ocular Surface Ocular Surface
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Ocular Surface] 的評論撰寫評論
作者: Melissa Henrietta


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-13 14:31:43 評論於
Can articles related to cataracts be submitted?
(0) 讚! | Melissa Henrietta

作者: 碧水春桃


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-28 14:56:30 評論於
Submitted two days ago and now in the "decision in process" stage, it has been a week already. Can anyone offer some advice?
(0) 讚! | 碧水春桃

作者: 哥天牛


領域: 医学
審稿時間: 2.0 month(s)
結果: 直接被接受


撰寫評論

2022-03-18 16:28:24 評論於
Is the roller coaster feeling from 10 to 5 very enjoyable?
(1) 讚! | 哥天牛

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 17:24:44 評論於
The judgment is usually based on the size of the research results and the length of the article
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 15:06:43 評論於
A research article is the main type of research paper published in journals, usually with a longer length and larger amount of research data
(0) 讚! | 维尔娜菲茨杰拉德

作者: 八坂篷蔚


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 20:58:13 評論於
What does research article mean?
(0) 讚! | 八坂篷蔚

作者: 上清雨真


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 17:14:09 評論於
How to determine the type of SCI articles?
(0) 讚! | 上清雨真

作者: 气甲胜换


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-03-07 10:57:36 評論於
Up to 5 points this year
(0) 讚! | 气甲胜换

作者: 安平小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-04-28 22:03:51 評論於
Seeking submission experience, how long does the first review usually take? Thank you
(0) 讚! | 安平小姐姐

作者: 安平小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-04-28 19:06:30 評論於
It has been a month since my article was submitted for review, and there has been no response yet. How long does the first review usually take?
(0) 讚! | 安平小姐姐

作者: 稻妻语薇


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-03-10 08:47:53 評論於
Hello, may I have the title of your article? I would like to read it. Thank you
(0) 讚! | 稻妻语薇

作者: Deborah Clare


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-20 17:04:19 評論於
Review speed: 2.0 | Submission hit rate: 25.0 Experience sharing: The first submission to ocular surface was not very hopeful, after all, it is the best journal in the field of ocular surface and is in the first quartile of ophthalmology. The first review came back in 19 days, with two reviews. One reviewer stated that the article was very innovative, with abundant data and very strong, and suggested direct acceptance; the second reviewer said the article was very meaningful and raised two small issues: adding a reference and discussing something in the discussion section. After revisions were made and the manuscript was delayed for ten days due to personal reasons, it was sent back. After staying with the editor-in-chief for a few days and then with the session editor for a few days, it was directly accepted without being sent back to the reviewers. Overall, I feel that this journal is very efficient, and Elsevier's journals are very friendly to authors. The progress of the manuscript is very clear. Ocular surface mainly accepts clinical articles and reviews in ophthalmology. I submitted a basic research article and didn't expect it to go smoothly. Luck should also be an important factor, and I think the editor happened to really like this topic
(0) 讚! | Deborah Clare

作者: 极乐迎蕊


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-02-14 11:11:27 評論於
Review speed: 3.0 | Acceptance rate: 5.0 Experience Sharing: A quarterly authoritative journal on ocular diseases, with few articles from Chinese authors
(0) 讚! | 极乐迎蕊

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-16 13:08:55 評論於
Stuck at this juncture, it's not easy to push on further in the journal, but getting over 4 points is quite satisfying
(0) 讚! | 凌霄高洁

作者: 孤云平彤


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2013-04-21 10:08:07 評論於
Please translate the following paragraph into English and Japanese, and title them as ":" and ":"
(0) 讚! | 孤云平彤

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-06-29 21:27:25 評論於
Will it drop to 3 points next year? If it drops below 3 points, it won't be worth it
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-06-29 15:07:41 評論於
Will it drop again next year? What if it falls below?
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Ocular Surface] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*